Management options for refractory depression

American Journal of Medicine

Volumn 101, Issue 6 A, 1996, Pages 45S-52S

  Nierenberg, Andrew A ^a   McColl, Rachel D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BENZODIAZEPINE; BROMOCRIPTINE; DEXAMPHETAMINE; LITHIUM; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; PEMOLINE; PERGOLIDE; PINDOLOL; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ANTIDEPRESSANT AGENT;

ALCOHOL ABUSE; BEHAVIOR THERAPY; COGNITIVE THERAPY; CONFERENCE PAPER; COPING BEHAVIOR; DEPRESSION; ELECTROCONVULSIVE THERAPY; MANIC DEPRESSIVE PSYCHOSIS; MENTAL STRESS; PRIORITY JOURNAL; PUERPERAL DEPRESSION; SUBSTANCE ABUSE; DRUG COMBINATION; HUMAN; PRIMARY HEALTH CARE; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; PRIMARY HEALTH CARE;

EID: 0030607625     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00397-x     Document Type: Conference Paper

References (81)

1. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed. Washington, DC: American Psychiatric Association, 1994.
2. Rush A, Kupfer D. Strategies and tactics in the treatment of depression. In: Gabbard GO, ed. Treatment of Psychiatric Disorders, 2nd edition. Washington, DC: American Psychiatric Press, 1995:1349.
3. Schatzberg A, Rothschild A. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? [Review.] Am J Psych. 1992;149:733-745.
4. Nierenberg A. The treatment of severe depression: is there an efficacy gap between selective serotonin reuptake inhibitors and tricyclic antidepressant generations? [Review.] J Clin Psych. 1994;55:55-61.
5. Clerc G, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 1994;9:139-143.
6. Roose S, Glassman A, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psych. 1994;151:1735-1739.
7. Parsons B, Quitkin F, McGrath PJ, et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull. 1989;25:524-534.
8. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine vs imipramine in atypical depression. Arch Gen Psych. 1984;41:669-677.
9. Boyer W. Potential indications for the select serotonin reuptake inhibitors [Review.] Int Clin Psychopharmacol. 1992;6:5-12.
10. Osser D. A systematic approach to the classification and pharmacotherapy of nonpsychotic major depression and dysthymia [Review.] J Clin Psychopharmacol. 1993;13:133-144.
11. Charney D, Nelson J. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psych. 1981;138:328-333.
12. Kessler R, Nelson C, McGonagle K, Liu J, Swartz M, Blazer D. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the National Comorbidity Survey. Br J Psych. 1996;168:17-30.
13. Kessler R, McGonagle K, Zhao S, et al. Lifetime and twelve-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psych. 1994;51:8-19.
14. Van Praag H. Comorbidity (psycho) analysed. Br J Psych. 1996;168:129-134.
15. Hudson J, Pope H. Affective spectrum disorder: does antidepressant response identify a family of disorders with a common pathophysiology? [Review.] Am J Psych. 1990;147:552-564.
16. Worthington J, Fava M, Agustin C, et al. Consumption of alcohol, nicotine, and caffeine among depressed outpatients: relationship with response to treatment. Psychosomatics. 1996;37:518-522.
17. Stowe Z, Nemeroff C. Women at risk for peripartum-onset major depression. Am J Obstet Gynecol. 1995;173:639-645.
18. Gregoire A, Kuman R, Everitt B, Henderson A, Studd J. Transdermal oestrogen for treatment of severe postnatal depression. Lancet. 1996;347:903-903.
19. Prien RF, Kupfer DJ, Mansky PA, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: a report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psych. 1984;41:1096-1104.
20. Rosenbaum JF, Quitkin FM, Fava M, et al. Fluoxetine vs. placebo: long-term treatment of MDD. Proceedings of the American College of Neuropsychopharmacology; 32nd Annual Meeting; Maui, HI; 1993.
21. Cohen L, Altshuler L, Heller V, Rosenbaum J. Psychotropic drug use in pregnancy. In: Bassuk S, Gelenberg, eds. The Practitioner's Guide to Psychotropic Drugs. New York: Plenum Medical Book Co. In press.
22. Hooley J, Orley J, Teasdale J. Levels of expressed emotion and relapse in depressed patients. Br J Psych. 1986;148:642-647.
23. Brown G, Harris T. Social Origins of Depression: A Study of Psychiatric Disorders in Women. New York: Free Press, 1978.
24. Russo J, Vitaliano P, Brewer D, Katon W, Becker J. Psychiatric disorders in spouse caregivers of care recipients with Alzheimer's disease and matched controls: a diathesis-stress model of psychopathology. J Abnorm Psych. 1995;104:197-204.
25. Price L. Lithium augmentation in tricyclic-resistant depression. In: Extein I, ed. Treatment of Tricyclic-Resistant Depression. Washington, DC: American Psychiatric Press, 1989:51-79.
26. Montgomery S. Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. [Review.] Psychopharmacology. 1995;10:23-27.
27. Beasley C, Sayler M, Weiss A, Potvin J. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992;12:328-333.
28. Fabre L, Abuzzahab F, Amin M, et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psych. 1995;38:592-602.
29. Schweitzer E, Rickels K, Amsterdam JD. What constitutes an adequate antidepressant trial for fluoxetine? J Clin Psych. 1990;51:8-11.
30. Fava M, Rosenbaum JF, Cohen L, et al. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord. 1992;25:229-234.
31. Rudolph R, Fabre L, Feighner J, Rickels K. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. In press.
32. Richelson E. Side effects of old and new generation antidepressants: a pharmacologic framework. J Clin Psych Monogr. 1991;9:13-19.
33. Nierenberg AA, McLean NE, Fava M, Alpert JE, Worthington JJ III, Rosenbaum JF. Early non-response to fluoxetine as a predictor of poor eight-week outcome. Am J Psych. 1995;152:1500-1503.
34. de Montigny C, Grunberg F, Mayer A. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psych. 1981;138:252-256.
35. Nierenberg A, Rosenbaum J. Antidepressant augmentation strategies II: lithium augmentation. Am Soc Clin Psychopharmacol Progr Notes. 1992;3:3-4.
36. Maes M, Meltzer H, Cosyns P, et al. An evaluation of basal hypothalamic-pituitary-thyroid axis function in depression: results of a large-scaled and controlled study. Psychoneuroendocrinology. 1993;18:607-620.
37. Hall R, Dunlap P, Hall R, et al. Thyroid disease and abnormal function tests in women with eating disorders and depression. J Fla Med Assoc. 1995;82:187-192.
38. Prange A, Wilson I, Rabon A, Lipton M. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psych. 1970;126:457-469.
39. Wilson I, Prange A, McClane T, Rabon A, Lipton M. Thyroid hormone replacement in nonretarded depression. N Engl J Med. 1970;282:1063-1067.
40. Coppen A, Whybrow P, Noguera R, Maggs R, Prange A. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psych. 1972;26:234-241.
41. 4-replaced thyroid patients. J Clin Psych. 1992;53:16-18.
42. Joffe R, Singer W, Levitt A, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psych. 1993;50:387-393.
43. Johnson M, Lichtenstein L. Thyroid function and treatment strategies in affective illness. Am Soc Clin Psychopharmacol Progr Notes. 1996;7.
44. Howland R. Biochemical and clinical effects of buspirone augmentation. [Letter.] J Clin Psych. 1994;55:264.
45. Howland R. Biochemical effects of antidepressant augmentation. [Letter.] Arch Gen Psych. 1995;52:156.
46. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15:217-222.
47. Artigas F. Pindolol, 5-hydroxytryptamine and antidepressant augmentation. [Letter.] Arch Gen Psych. 1995;52:969-971.
48. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psych. 1994;51:248-251.
49. Moreno F, Delgado P, Bachar K, Gelenberg A. Pindolol augmentation in treatment-resistant depression. (Abstr.) NCDEU 36th Annual Meeting. May 28-3, 1996; Boca Raton, FL.
50. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical review. J Clin Psych. 1989;50:241-249.
51. Chiarello RJ, Cole JO. The use of psychostimulants in psychiatry. Arch Gen Psych. 1987;44:286-295.
52. Warneke L. Psychostimulants in psychiatry. Can J Psych. 1990;35:3-10.
53. Smith W, Londberg P, Glaudin V, Painter J. Clonazepam augmentation of fluoxetine in the treatment of outpatients with major depression: a double-blind, placebo-controlled, multicenter study. NCDEU 36th Annual Meeting; May 28-31, 1996; Boca Raton, FL.
54. Baron BM, Ogden AM, Siegel BW, Stegeman J, Ursillo RC, Dudley MW. Rapid down-regulation of beta-adrenoceptors by coadministration of desipramine and fluoxetine. Eur J Pharmacol. 1988;154:125-134.
55. Weilburg JB, Rosenbaum JF, Biederman MD, Sachs GS, Pollack MH, Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psych. 1989;50:447-449.
56. Aranow A, Hudson J, Pope H, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psych. 1989;146:911-913.
57. Andrews J, Nemeroff C. Contemporary management of depression. Am J Med. 1994;97:245-325.
58. Labbate L, Pollock M. Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report. Ann Clin Psych. 1994;6:13-15.
59. Golden R, DeVane C, Laizure S, Rudorfer M, Sherer M, Potter W. Bupropion in depression: the role of metabolites in clinical depression. Arch Gen Psych. 1988;45:145-149.
60. Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psych. 1992;53:83-85.
61. Nierenberg A, Keck P. Management of monoamine oxidase inhibitor associated insomnia with trazodone. J Clin Psychopharmacol. 1989;9:42-45.
62. Nierenberg A, Adler L, Peselow E, Zomberg G. Trazodone for antidepressant-associated insomnia. Am J Psych. 1994;151:1069-1072.
63. Amsterdam J, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuropsychopharmacol Biol Psych. 1994;18:243-261.
64. Brown W, Harrison W. Are patients who are intolerant of one SSRI intolerant to another? Psychopharmacol Bull. 1992;28:253-256.
65. Apter J, Thase M, Birkett M. Fluoxetine treatment in depressed patients who failed treatment with sertraline. (Abstr.) NCDEU 36th Annual Meeting; May 28-31, 1996; Boca Raton, FL.
66. Neirenberg AA, Feighner JF, Rudolph RR, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419-423.
67. de Montigny C, Debonnel G, Bergeron R, St.-Andre E, Blier P. Venlafaxine in treatment-resistant depression: an open label multicenter study. American College of Neuropsychopharmacology, 34th Annual Meeting; Dec 11-15, 1995; San Juan, Puerto Rico.
68. Thase ME, Fava M, Halbreich U, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 1996;53:777-784.
69. Sternbach H. The serotonin syndrome. Am J Psych. 1991;148:705-713.
70. Weiner R. Electroconvulsive therapy. In: Gabbard GO, ed. Treatments of Psychiatric Disorders, 2nd ed. Washington, DC: American Psychiatric Press; 1995:1237.
71. Casey P, Meagher D, Butler E. Personality, functioning and recovery from major depression. J Nerv Ment Dis. 1996;184:240-245.
72. Kling M, Geracion T, Licinio J, Michelson D, Oldfield E, Gold P. Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings. [Review.] Psychopharmacol Bull. 1994;30;489-494.
73. Hermann R, Dorwart R, Hoover C, Brody J. Variation in ECT use in the United States. Am J Psych. 1995;152:869-875.
74. Devanand D, Dwork A, Hutchinson E, Bolwig T, Sackein H. Does electroconvulsive therapy alter brain structure? [Review.] Am J Psych. 1994;151:957-970.
75. Thase M. Reeducative therapies. In: Gabbard GO, ed. Treatments of Psychiatric Disorders, 2nd ed. Washington, DC: American Psychiatric Press, 1995:1169.
76. Jamison C, Scogin F. The outcome of cognitive bibliotherapy with depressed adults. J Consult Clin Psychol. 1995;63:644-650.
77. Regier D, Narrow W, Rae D, Manderscheid R, Locke B, Goodwin F. The de facto U.S. mental health and addictive disorders service system: epidemiologic catchment area propsective one-year prevalence rates of disorders and services. Arch Gen Psych. 1993; 50:85-94.
78. Kreitman N. Parasuicide. New York, NY:Wiley, 1977.
79. Gibbons J, Pierce D. Estimating suicidal risk among attempted suicides, II: efficacy of predictive scales after the attempt. Br J Psych. 1984;144:138-148.
80. Awouters F, Niernegeer C, Janssen P. Tardive dyskinesia: etiological and therapeutic aspects. [Review.] Pharmacopsychiatry. 1990;23:33-37.
81. Burke R. Current clinical issues. Neurology. 1984;34:1348-1353.